Bioverse: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.gobioverse.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.

1. 1

   “"Same active ingredient as Ozempic and Wegovy" "The same active ingredient in Mounjaro and Zepbound"”

2. 2

   “"Doctor-trusted ingredients, formulated with the same active ingredient as Ozempic and Wegovy"”

3. 3

   “"Weight loss specialists frequently prescribe compounded semaglutide, which contains the same active ingredient as Ozempic and Wegovy"”

4. 4

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

gobioverse.com returned a live storefront when we checked in August 2026, with semaglutide and tirzepatide listed among its popular treatments alongside a wider longevity catalogue including NAD+, glutathione and hair loss.

Two of the five claims FDA quoted here work by borrowing credibility rather than stating a fact about the product: "doctor-trusted" and "weight loss specialists frequently prescribe." Neither is a price claim, and neither says anything about the cost of a Bioverse plan. What they do is put a professional endorsement next to a brand-name comparison, so a reader arrives at the price already primed to treat the compounded product as a cheaper version of the approved one. When a page pairs an authority signal with a same-ingredient line, treat the price as a price and the endorsement as marketing — FDA's position is that the two together overstate what has been established about the compounded product.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Bioverse failed to respond.